The Exxel Group

Exxel Pharma is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for central nervous system (CNS) disorders and inflammatory conditions. The company's lead program, EXX-001, is a potent and selective monoacylglycerol lipase (MAGL) inhibitor currently being evaluated for the treatment of post-traumatic stress disorder (PTSD) and chronic pain. By targeting the endocannabinoid system, Exxel Pharma aims to provide non-opioid alternatives for pain management and address significant unmet needs in mental health. The company's pipeline also includes discovery-stage programs exploring MAGL inhibition in other neurological indications such as Tourette syndrome and addiction.